Pfizer Says Big Deals Create Value & 10 Other Notable Q3 Moments
Pfizer's third quarter earnings call covered a lot of ground, from pipeline updates, management's latest thinking on M&A, and strategic options for consumer healthcare, to industry trends like Amazon entering the drug distribution arena.
You may also be interested in...
Bolt-ons or big-ticket buys? As another year passes without a big pharma mega merger despite industry giants sitting on large cash piles, we consider whether 2018 will bring major upheaval in the industry landscape, and where M&A will be most likely to take place.
Results from a number of Phase III studies in non-small cell lung cancer for major immuno-oncology players are coming soon, with potential to change the market dynamics.
Top-line Phase III data from the MONALEESA-7 study could lead to an extension of Kisqali's indications into pre-menopausal women with a certain type of breast cancer, helping it gain traction in the highly competitive CDK4/6 inhibitor market.